Bone Neoplasms News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

Blueprint Medicines Announces New Data from Ongoing Phase 1 Clinical Trial of Avapritinib (BLU-285) in Patients with ... - Markets Insider



Blueprint Medicines Announces New Data from Ongoing Phase 1 Clinical Trial of Avapritinib (BLU-285) in Patients with ... 
Markets Insider
As of the data cutoff date of October 4, 2017, the data showed an overall response rate (ORR) of 72 percent and a disease control rate (DCR) of 100 percent in patients evaluable for response, based on the International Working Group-Myeloproliferative ...

and more » 


Effective treatment of low-dose decitabine in myelodysplastic syndrome/myeloproliferative neoplasms - Dove Medical Press



Effective treatment of low-dose decitabine in myelodysplastic syndrome/myeloproliferative neoplasms 
Dove Medical Press
Materials and methods: A female patient was diagnosed with MDS/MPN through bone marrow cytology, immunology, cell genetics, molecular biology, and pathology. She received thalidomide and prednisone as initial treatment. Ten months later, the first-line ...

 


PharmaEssentia Announces Favorable Two-year Results of ... - Markets Insider



PharmaEssentia Announces Favorable Two-year Results of ... 
Markets Insider
WALTHAM, Mass., Dec. 10, 2017 /PRNewswire/ -- PharmaEssentia USA, a subsidiary of PharmaEssentia Corporation (Taipei Exchange: 6446), today announced the latest follow-up results of Ropeginterferon alfa-2b from the ongoing, long-term, follow-up trial ...

and more » 


Plasma Cell Neoplasm Treatment Market report 2017 ? 2025: By Treatment Type, Disease Indication, End User, by ... - satPRnews (press release)



Plasma Cell Neoplasm Treatment Market report 2017 ? 2025: By Treatment Type, Disease Indication, End User, by ... 
satPRnews (press release)
Continuous development of new therapies by the pharmaceutical companies and development of biologics treatment options are also expected to boost the growth of the plasma cell neoplasm treatment market. Increasing development of generics & biosimilars ...

and more » 


Geron: It's Breakout Time - Seeking Alpha



Geron: It's Breakout Time 
Seeking Alpha
With a potential market size potentially exceeding $15 Billion, Geron's late-stage drug Imetelstat has first-tier blockbuster potential. Imetelstat is licensed to Janssen, the pharmaceutical division of Johnson and Johnson (JNJ). Not only is Imetelstat ...

and more » 


Myeloproliferative Neoplasms Treatment Market By Drug (Jakfi) ? Global Industry Insights, Trends, Outlook, And ... - Medgadget (blog)



Myeloproliferative Neoplasms Treatment Market By Drug (Jakfi) ? Global Industry Insights, Trends, Outlook, And ... 
Medgadget (blog)
Myeloproliferative Neoplasms (MPNs) are a group of rare disease, in which the bone marrow produces excess blood cells. It can be white blood cells, red blood cells or platelets. The overproduction of blood cells by the bone marrow creates hindrance in ...

 


In The Spotlight: Stemline Therapeutics - Nasdaq



KL Daily
 
In The Spotlight: Stemline Therapeutics 
Nasdaq
SL-401 is under a phase II potentially pivotal trial in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). BPDCN is a rare and aggressive hematologic malignancy of the bone marrow and blood that can affect other organs such as the ...
Stemline Therapeutics, Inc. - STML - Stock Price Today - Zacks Zacks Investment Research

all 22 news articles » 


ACVP 2017: Key Features of the Middle Ear in Veterinary Species - American Veterinarian



American Veterinarian
 
ACVP 2017: Key Features of the Middle Ear in Veterinary Species 
American Veterinarian
Presenting at the American College of Veterinary Pathologists 2017 Annual Meeting in Vancouver, British Columbia, Canada, Dr. Njaa also reviewed some anatomic and biological features of the middle ear in domestic animals, highlighting how some of these ...

 


PharmaEssentia Announces Favorable Two-year Results of Ropeginterferon Alfa-2b in Polycythemia Vera at the ... - MENAFN.COM



PharmaEssentia Announces Favorable Two-year Results of Ropeginterferon Alfa-2b in Polycythemia Vera at the ... 
MENAFN.COM
PharmaEssentia was founded in 2003 by a group of Taiwanese-American executives and high-ranking scientists from leading U.S. biotechnology and pharmaceutical companies in order to develop treatments for myeloproliferative neoplasms, hepatitis and other ...

 


Incyte Starts Clinical Trial Of Ruxolitinib For Essential Thrombocythemia - Markets Insider



Incyte Starts Clinical Trial Of Ruxolitinib For Essential Thrombocythemia 
Markets Insider
ET is a rare, chronic blood cancer, part of a group of related blood cancers known as myeloproliferative neoplasms or MPNs, characterized by increased platelet production, a white cell count above the normal range, persistently elevated platelet counts ...

and more »